Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023

Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will release its fourth quarter and full year 2022 financial results on February 22, 2023, after the market closes. A conference call is scheduled for 4:30 PM Eastern Time to discuss the results, which will be accessible via a webcast on their Investor Center website. The company emphasizes innovation in insulin delivery, particularly with its t:slim X2 insulin pump featuring Control-IQ technology, aimed at improving diabetes management. Further details will be available post-event on the website.

Positive

• Innovative product offerings like the t:slim X2 insulin pump with Control-IQ technology enhance diabetes management.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2022 results after the financial markets close on Wednesday, February 22, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2022 financial and operating results.

A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section. To access the call by phone, please use this link (https://register.vevent.com/register/BI676b1bca7fca4eeaa60be7e9c39f206b) and you will be provided with dial-in details, including a personal pin.

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care is a registered trademark and t:slim X2 and Control-IQ are trademarks of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005623/en/

Media Contact:

858-255-6388

media@tandemdiabetes.com



Investor Contact:

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.

FAQ

When will Tandem Diabetes Care announce its Q4 and full year 2022 results?

Tandem Diabetes Care will announce its Q4 and full year 2022 results on February 22, 2023.

What time is the conference call for Tandem Diabetes Care's Q4 results?

The conference call for Tandem Diabetes Care's Q4 results is scheduled for 4:30 PM Eastern Time on February 22, 2023.

Where can I listen to the webcast of Tandem Diabetes Care's financial results?

You can listen to the webcast on Tandem Diabetes Care's Investor Center website.

What product does Tandem Diabetes Care's innovation focus on?

Tandem Diabetes Care focuses on the t:slim X2 insulin pump with Control-IQ technology.